ReviewFrontiers in psychiatry2014
A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation.
Review in Frontiers in psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia.International journal of molecular sciences · 2023Pooled it
- Acetylsalicylic acid (aspirin) for schizophrenia.The Cochrane database of systematic reviews · 2019Pooled it
- Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis.Acta neuropsychiatrica · 2019Trial
- The Course of Neurocognitive Changes in Acute Psychosis: Relation to Symptomatic Improvement.PloS one · 2016Trial
- The Role of Cerebrolysin in Promoting Axonal Regeneration and Functional Recovery after Peripheral Nerve Injury: A Focus on Macrophage Activation.Advanced pharmaceutical bulletin · 2025Article
- Associations Between Klotho Levels,Schizophrenia bulletin open · 2025Article
- The Effects of Antipsychotics in Experimental Models of Krabbe Disease.Biomedicines · 2023Article
- A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia.Brain sciences · 2023Review
- Article
- Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia.CNS drugs · 2022Review
- Glutamate Transporters: Expression and Function in Oligodendrocytes.Neurochemical research · 2020Article
- Serum C-Reactive Protein in Patients with Deficit Schizophrenia and the Relationship with Cognitive Function.Neuropsychiatric disease and treatment · 2020Article
- Potential drug targets and treatment of schizophrenia.Inflammopharmacology · 2017Review
- Cyclin-dependent kinase inhibitor flavopiridol promotes remyelination in a cuprizone induced demyelination model.Cell cycle (Georgetown, Tex.) · 2016Article
- The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis.BMC psychiatry · 2016Article
- The search for new biomarkers for cognition in schizophrenia.Schizophrenia research. Cognition · 2015Review
- Neurobiology of cognitive remediation therapy for schizophrenia: a systematic review.Frontiers in psychiatry · 2014Review
- Neuropsychopharmacology of psychosis: relation of brain signals, cognition, and chemistry.Frontiers in psychiatry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antipsychotic drugs have thus far focused on dopaminergic antagonism at the D2 receptors, as counteracting the hyperdopaminergia in nigrostriatal and mesolimbic projections has been considered mandatory for the antipsychotic action of the drugs. Current drugs effectively target the positive symptoms of psychosis such as hallucinations and delusions in the majority of patients, whereas effect sizes are smaller for negative symptoms and cognitive dysfunctions. With the understanding that neurocognitive dysfunction associated with schizophrenia have a greater impact on functional outcome than the positive symptoms, the focus in pharmacotherapy for schizophrenia has shifted to the potential effect of future drugs on cognitive enhancement. A major obstacle is, however, that the biological underpinnings of cognitive dysfunction remain largely unknown. With the availability of increasingly sophisticated techniques in molecular biology and brain imaging, this situation is about to change with major advances being made in identifying the neuronal substrates underlying schizophrenia, and putative pro-cognitive drug targets may be revealed. In relation to cognitive effects, this review focuses on evidence from basic neuroscience and clinical studies, taking two separate perspectives. One perspective is the identification of previously under-recognized treatment targets for existing antipsychotic drugs, including myelination and mediators of inflammation. A second perspective is the development of new drugs or novel treatment targets for well-known drugs, which act on recently discovered treatment targets for cognitive enhancement, and which may complement the existing drugs. This might pave the way for personalized treatment regimens for patients with schizophrenia aimed at improved functional outcome. The review also aims at identifying major current constraints for pro-cognitive drug development for patients with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.